Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1


  1. 1

    Vardiman JW, Arber DA, Brunning RD, Larson RA, Matutes E, Baumann I et al. Therapy-related myeloid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, France, 2008; pp 214–217.

    Google Scholar 

  2. 2

    Morton LM, Dores GM, Tucker MA, Kim CJ, Onel K, Gilbert ES et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood 2013; 121: 2996–3004.

    CAS  Article  Google Scholar 

  3. 3

    Ramadan SM, Suciu S, Stevens-Kroef MJPL, Willemze R, Amadori S, Witte Td et al. Survival improvement of secondary acute myeloid leukemia over time: experience from 962 patients included in 13 EORTC-Gimema-HOVON Leukemia Group Trials. Blood 2013; 122: 829a.

    Google Scholar 

  4. 4

    Khoury JD, Sen F, Abruzzo LV, Hayes K, Glassman A, Medeiros LJ . Cytogenetic findings in blastoid mantle cell lymphoma. Hum Pathol 2003; 34: 1022–1029.

    CAS  Article  Google Scholar 

  5. 5

    Giordano A, Gao H, Cohen EN, Anfossi S, Khoury J, Hess K et al. Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. Ann Oncol 2013; 24: 2515–2521.

    CAS  Article  Google Scholar 

  6. 6

    O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E et al. Acute myeloid leukemia. J Natl Compr Cancer Netw 2012; 10: 984–1021.

    CAS  Article  Google Scholar 

  7. 7

    Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454–2465.

    CAS  Article  Google Scholar 

  8. 8

    Rosato V, Bosetti C, Talamini R, Levi F, Montella M, Giacosa A et al. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol 2011; 22: 2687–2692.

    CAS  Article  Google Scholar 

  9. 9

    Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003; 95: 1218–1226.

    CAS  Article  Google Scholar 

  10. 10

    Balkwill F, Charles KA, Mantovani A . Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211–217.

    CAS  Article  Google Scholar 

  11. 11

    Kaye JA, Meier CR, Walker AM, Jick H . Statin use, hyperlipidaemia, and the risk of breast cancer. Br J Cancer 2002; 86: 1436–1439.

    CAS  Article  Google Scholar 

  12. 12

    Liao S, Li J, Wei W, Wang L, Zhang Y, Li J et al. Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer Prev 2011; 12: 1061–1065.

    PubMed  PubMed Central  Google Scholar 

  13. 13

    Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 2005; 103: 1122–1128.

    CAS  Article  Google Scholar 

  14. 14

    Armand P, Kim HT, Mayer E, Cutler CS, Ho VT, Koreth J et al. Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy. Bone Marrow Transplant 2010; 45: 1611–1617.

    CAS  Article  Google Scholar 

  15. 15

    Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 2014; 518: 552–555.

    Article  Google Scholar 

Download references


This work was supported by the National Cancer Institute (CA016672, MD Anderson Cancer Center Support Grant); the Slovak Grant Agency (VEGA 1/0724/11 to MM); and the Slovak Research and Development Agency (APVV-0016-11 to KS and MM). We thank Sherry Pierce (Leukemia) and Limin Hsu (Breast Medical Oncology) for assistance with database queries. We also thank Leiloni Gilbert for administrative support.

Author Contributions

Khoury: Conception and design of study, data analysis, and manuscript preparation. Sevcikova and Zuo: Data collection, data analysis, and manuscript preparation. Zuo: Statistical analysis. Garcia-Manero, Alvarez, Kantarjian, Mego, Albarracin, Tang, Strom, Medeiros, Hortobagyi, and Reuben: Data analysis and manuscript preparation. All the authors read and approved the final manuscript.

Author information



Corresponding author

Correspondence to J D Khoury.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

This work has been presented at the 2014 American Society for Hematology annual meeting and the Society for Hematology and Oncology annual meeting.

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sevcikova, K., Zhuang, Z., Garcia-Manero, G. et al. Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment. Leukemia 30, 243–247 (2016).

Download citation

Further reading